Baiyunshan released its 2026 interim report. Net profit attributable to the parent company was 2.096 billion yuan, a decrease of 420 million yuan from the same period last year, down 16.70% year-on-year. Total operating revenue was 42.091 billion yuan, an increase of 256 million yuan from the same period last year, up 0.61% year-on-year, achieving five consecutive years of growth. Net cash flow from operating activities was negative 270 million yuan, an increase of 3.127 billion yuan from the same period last year. The company's latest asset-liability ratio was 52.76%, gross margin was 17.27%, ROE was 5.36%, and diluted earnings per share was 1.29 yuan.
Guangzhou Baiyunshan Pharmaceutical Holdings Co LtdNet profit attributable to parent fell 16.70% year-on-year to 2.096 billion yuan.
